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Observations and Research
Exploring the Effects of Cigarette Smoking on 
Inflammatory Bowel Disease Using Mendelian 
Randomization
Daniel P. Jones, BMBCh,*,†,  Tom G Richardson, PhD,*,‡ George Davey Smith, PhD,*,‡,§  
David Gunnell, PhD, MD,*,§ Marcus R. Munafò, PhD,‡,§,¶,‖ Robyn E. Wootton, PhD‡,§,‖   
Background. Previous observational evidence has suggested an association between smoking and inflammatory bowel disease (IBD).
Methods. We used observational techniques followed by Mendelian randomization to explore whether smoking is a causal factor in the devel-
opment of IBD and its subtypes.
Results. In those who have ever smoked, we observed increased risk of IBD and, in current smokers, we observed increased risk of Crohn 
disease and decreased risk of ulcerative colitis. However, our Mendelian randomization analyses found little evidence that smoking affects the 
development of IBD.
Conclusion. Overall, our results suggest that smoking does not causally influence the risk of IBD.
Lay summary
A study investigating the effect of smoking on the risk of developing inflammatory bowel disease using observational and genetic tools. Despite 
strong observed associations, our overall results suggest smoking does not affect the risk of developing inflammatory bowel disease.
Key words.  smoking, inflammatory bowel disease, Mendelian randomization, UK Biobank
INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic condition 
affecting the gut. It presents in one of the two distinct clin-
ical categories: Crohn disease and ulcerative colitis (UC). The 
prevalence of IBD in UK is 1% within the adult population 
and commonly manifests with chronic symptoms of abdom-
inal pain, weight loss, and diarrhea as well as acute flares that 
can result in hospitalization, surgical interventions, and even 
death.1 It represents a substantial source of morbidity and is 
often difficult to manage medically.
Tobacco smoking is associated with both risk and clin-
ical course of IBD. Ever smokers have an overall greater risk 
of developing IBD than never smokers2 (OR = 1.64 [95% CI 
1.36–1.98] for UC, 1.80 [95% CI 1.33–2.51] for Crohn dis-
ease). The risk of developing IBD also differs between those 
who currently smoke and those who have previously smoked 
although this relationship varies depending on the clinical 
subtype. In a recent meta-analysis of 22 case–control studies, 
it was observed that current smokers have an increased risk 
of developing Crohn disease compared with former smokers 
(OR = 1.76 [95% CI 1.40–2.22]), whilst current smokers have 
a reduced risk of developing UC compared with former 
smokers3 (OR = 0.58 [95% CI 0.45–0.75]). This meta-analysis 
also highlighted a markedly increased risk of developing UC 
in the year following smoking cessation (OR = 1.79 [95% CI 
1.37–2.34]).
doi: 10.1093/crocol/otaa018
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Following disease onset, smoking in Crohn disease has 
also been associated with a worse clinical course, in terms of 
recurrence, need for surgical interventions, and disease com-
plications.4 In contrast, the effect of smoking on the clinical 
course of UC appears to be protective in terms of recurrence, 
hospitalizations, and symptoms5 although there is some con-
flicting evidence.6, 7
The observational evidence certainly suggests an associa-
tion between smoking and risk of IBD. There are several plau-
sible mechanisms by which smoking could affect the etiology 
and course of IBD, including effects on the immune system 
and gut permeability.8 Tobacco smoke has also been shown to 
modify the association of certain genetic variants with risk of 
developing Crohn disease and UC.9 However, the observational 
evidence may well not represent true causation, given that obser-
vational data could be subject to bias from confounding (such 
as socioeconomic status or alcohol use) and reverse causation. 
One method that can be used to reduce bias from confounding 
and reverse causation is Mendelian randomization (MR).
MR is an instrumental variable analysis that uses genetic 
variants as proxies for an exposure (eg, smoking) to estimate 
the causal effect on an outcome (eg, IBD). Genetic variants are 
randomly inherited at conception and should therefore be inde-
pendent of confounding factors. As genetic variants are stable 
over the lifetime, the genetic instrument cannot be changed by 
the outcome, therefore, insuring there is no reverse causation10 
(see Figure  1). MR can be conducted using measured geno-
types, exposure, and outcome in a single sample, known as 
individual-level MR. Alternatively, summary-level MR can be 
conducted which uses genome-wide association study (GWAS) 
summary data from independent samples. This helps to signif-
icantly increase statistical power and avoids the cost and dif-
ficulty associated with measuring both the exposure and the 
outcome in the same sample. We used both MR methods to 
estimate the causal effect of smoking on risk of IBD to further 
elucidate the etiology of this complex disease.
In order to infer causality in MR, the genetic instrument 
must satisfy three assumptions: (1) the genetic variants must 
robustly predict the exposure of interest (with stronger instru-
ments giving better power to detect effects), (2) the genetic 
variants must not predict confounding factors that affect the 
exposure and/or outcomes, and (3) the genetic variants must 
only affect the outcome via the exposure.11 Violation of these 
assumptions can occur in MR due to pleiotropy (where one ge-
netic variant has multiple biological effects).12 We conducted 
multiple sensitivity analyses to ensure our results are reliable 
and not biased by pleiotropy.
In summary, we aimed to replicate previous observational 
associations between smoking and IBD subtypes. We followed 
up these associations using two MR methods to test whether 
there was evidence of smoking being a causal risk factor for 
IBD. Consistent effects triangulated across multiple MR 




Analysis was conducted using the UK Biobank, a large 
national health resource aged 39–72  years at recruitment 
(mean 56.9 years [SD 8.00]). Over 500,000 participants were re-
cruited between 2006 and 2010 from study centers across the 
UK. Further details can be found at www.ukbiobank.ac.uk. 
Individuals were excluded if  they had withdrawn consent or 
if  there were sex mismatches between reported and chromo-
somal sex or aneuploidy (N = 814). Individuals were restricted 
to European ancestry based on the first four principal compo-
nents of population structure and related individuals were re-
moved following MRC Integrative Epidemiology Unit filtering 
steps. The result was a sample of 337,053 individuals (54% fe-
male, 45% ever smokers (10% current; 35% former)).
Measures of IBD 
Individuals were classified from hospital records as 
having a diagnosis of either Crohn disease or UC using ICD 
10 codes K50 and K51 (field 41202). Individuals were classified 
as having IBD if  they had a diagnosis of either UC or Crohn 
disease. For the full sample, 1.1% had any diagnosis of IBD, 
0.4% had a diagnosis of Crohn disease, and 0.8% had a diag-
nosis of UC. When compared with the most recent study of a 
UK population, a similar 40- to 69-year-old cohort had preva-
lence of 1.1%, 0.4%, and 0.7% for IBD, Crohn disease, and UC, 
respectively.14
Statistical analysis 
We looked at the effect of four smoking behaviors on 
IBD collectively and on each subtype. These were smoking 
status (ever vs never), smoking status (current vs former within 
ever smokers), cigarettes per day (within ever smokers), and 
lifetime smoking score. The latter is a combination of smoking 
duration, smoking cessation, and smoking heaviness de-
scribed in detail elsewhere.15 The association between each of 
these smoking behaviors and IBD was estimated using logistic 
FIGURE 1. An illustration of MR principles where genetic variants (Z) 
are robustly associated with the exposure of interest (X) that in turn 
affects the outcome of interest (Y). These variants (Z) are not affected 
by confounding factors (U) or the outcome (Y) whereas the exposure 
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regression, controlling for age, sex, and socio-economic posi-
tion (SEP). All analyses were conducted using R.16
Individual-level MR Analysis
We conducted an individual-level MR analysis using 
a single single-nucleotide polymorphism (SNP) for smoking 
heaviness on IBD outcomes in the UK Biobank sample out-
lined above. We used the genetic variant rs1051730 (A/G) found 
in the gene cluster CHRNA5-A3-B4. This SNP is known to 
be associated with nicotine metabolism such that each allele 
increase in rs1051730 corresponds to an average of one more 
cigarette smoked per day.17–20
Genotype data 
UK Biobank participants provided blood samples at the 
initial assessment center. Genotyping was performed using the 
Affymetrix UK BiLEVE Axiom array for 49,979 participants 
and using the Affymetrix UK Biobank Axiom array for 438,398 
participants. The two arrays share 95% coverage, but the chip 
is adjusted for in all analyses because the UK BiLEVE sample 
is overrepresented for smokers. Imputation and initial quality 
control steps were performed by the Wellcome Trust Centre for 
Human Genetics resulting in over 90 million SNPs and indels. 
After excluding individuals who had withdrawn consent and 
using the most stringent ancestry exclusions, 337,053 of the 
participants remained.20 Participants’ genotype was categorized 
as 0,1, or 2 depending on the number of effect alleles (A).
Statistical analysis 
We first checked the rs1051730 genotype was associated 
with cigarettes per day in smokers and split participants into 
ever smokers, current smokers, former smokers, and never 
smokers (as a negative control). Second, we checked that the 
genotype was not associated with demographic variables in-
cluding age, sex, alcohol, and education. A logistic regression 
was run for genotype on each of the IBD outcomes adjusting 
for age and sex. Analysis was conducted in R, version 3.5.0.
Summary-level MR
Instruments for the exposure 
To construct our instruments for smoking exposure, we 
selected two smoking behaviors with known genetic proxies: 
smoking initiation and lifetime smoking. For smoking initia-
tion, we used summary data from the GSCAN GWAS21 which 
defined smoking initiation as ever having smoked more than 100 
cigarettes, smoking every day for at least a month or smoking 
regularly. The sample size was 1,232,091 and it identified 378 
independent genome-wide significant genetic loci which explain 
4% of the variance in smoking initiation. For lifetime smoking 
exposure, we used the “lifetime smoking index” which charac-
terizes exposure as a combination of smoking initiation, dura-
tion, heaviness, and cessation. This index was originally based 
on data from a GWAS in the UK Biobank13 which identified 
126 independent significant genetic loci in a population of 
462,690. For SNPs present in our instruments but not our out-
come summary data, we searched for suitable proxy SNPs from 
Phase 3 of the 1000 genomes project using the LDLink appli-
cation,22 with an R2 of at least 0.8. Our final instrument SNPs 
have not previously been found to associate with IBD.
Outcome summary data 
For the outcome of IBD, we used GWAS summary data 
from the most recent available GWAS.23 This study performed 
a case–control GWAS on 59,957 individuals of European 
Ancestry meta-analyzed across multiple cohorts. They identi-
fied 241 independent genome-wide significant SNPs, including 
25 novel loci. Individuals were categorized according to the 
diagnosed histological subtype of IBD (UC and Crohn disease) 
as well as a combined IBD category which encompassed con-
firmed cases of UC, Crohn disease, and unclassified IBD.
Statistical Analyses 
Analyses were conducted using the TwoSampleMR 
package 0.4.1824 in R version 3.5.1.13 We conducted the fol-
lowing MR methods: inverse-variance weighted (IVW),25 MR 
Egger SIMEX,26 weighted median,27 and weighted mode.28 
Consistent effects across multiple methods that each make 
different assumptions about pleiotropy give us the strongest 
evidence for causal inference. The validity of the MR Egger 
method was evaluated using the regression dilution I2 statistic.29 
If  the result was less than 0.9, then SIMEX corrections were 
conducted. We assessed the strength of the genetic instruments 
using the Mean F-statistic. A  value above 10 indicates good 
instrument strength.30 Bias from directional pleiotropy was 
specifically assessed using the MR Egger intercepts. We also 
applied Steiger filtering to remove the genetic variants that ex-
plain more variance in the outcome than the exposure31 as a test 
of reverse causation.
Data availability 
The data used in the summary level MR analysis are pub-
licly available via the cited references. The scripts used to con-
duct all analyses are available at https://github.com/MRCIEU/
Smoking_IBD.
Ethical Considerations
UK Biobank has received ethics approval from the UK 




The prevalence in the UK Biobank was 9.9% for cur-
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Crohn disease was 0.4% and UC was 0.8%. Observational ana-
lyses showed evidence for an association between smoking heav-
iness and risk of IBD but with small effect sizes (see Table 1). 
Smoking status (ever vs never) was associated with an increased 
risk of all IBD diagnoses whereas being a current smoker com-
pared with a former smoker increased risk of Crohn disease 
and decreased the risk of UC (see Table 1).
Individual-level MR Analysis
Each allele increase of rs1051730 genotype was associated 
with the expected increase of one more cigarette smoked per 
day on average among ever smokers (see Supplementary Table 
S1). In the single SNP analysis, strong evidence for a causal 
effect of smoking heaviness on IBD risk would be an effect in 
ever, current, or former smokers but no effect in never smokers. 
When looking at effects on IBD, there was only very weak evi-
dence of rs1051730 effect alleles increasing the risk of IBD and 
UC in ever, current, and former smokers compared with never 
smokers. There was no evidence for an effect on Crohn disease 
(see Figure 2). Supplementary Table S5 shows the association 
of rs1051730 genotype with sample demographics.
Summary-level MR Analysis
Of the 378 SNPs associated with smoking initiation, 325 
were available (or had suitable proxies) in the GWAS summary 
statistics for IBD. Of the 126 SNPs associated with lifetime 
smoking, 107 were available (or had suitable proxies) in the 
GWAS summary statistics for IBD.
Overall, there was limited evidence for an effect of 
smoking on IBD. Our results showed weak evidence for 
smoking increasing the risk of  developing Crohn disease 
(with notable effect sizes), but there was no clear evidence of 
an effect of  smoking on the risk of  IBD and UC. The confi-
dence intervals for our results were wide and all crossed the 
null (see Table 2).
Regression dilution I2 statistics were below 0.9 when 
smoking initiation was the exposure and below 0.6 for life-
time smoking (see Supplementary Table S2). Therefore, an un-
weighted MR Egger SIMEX correction was applied only to 
smoking initiation. Cochran’s Q-tests did provide evidence for 
heterogeneity (see Supplementary Table S3) but the MR Egger 
intercept did not differ from zero, suggesting the results were not 
biased by directional horizontal pleiotropy (see Supplementary 
Table S4). We calculated mean-F statistics to test instrument 
strength and all were greater than 10 (see Supplementary Table 
S2). We also carried out Steiger filtering to test for reverse cau-
sation. The majority of SNPs explained more variance in the 
exposure than in the outcome providing little evidence for re-
verse causation (see Supplementary Table S5). We ran our 
summary-level MR analysis with SNPs explaining more vari-
ance in the outcome excluded and obtained similar results (see 
Supplementary Table S6).
DISCUSSION
We used multiple methods to investigate cigarette 
smoking as a potential risk factor for IBD and its subtypes, 
UC, and Crohn disease. The results of our observational anal-
ysis suggested that ever smoking increases the risk of IBD and 
its subtypes compared with never smoking whilst being a cur-
rent vs former smoker increases the risk of Crohn disease and 
decreases the risk of UC, in line with previous observational lit-
erature.2, 3 This could suggest that exposure to tobacco smoking 
is a causal risk factor in the development of IBD overall, but 
that smoking cessation specifically decreases the risk of Crohn 
disease whilst increasing the risk of UC.
However, our summary-level MR results provided little 
evidence that smoking increases the risk of developing Crohn 
disease or UC particularly and, to an even lesser extent, IBD. If  
such an effect exists, then it is likely to be small. We found some 
evidence for an effect of smoking on the risk of developing UC 
in our individual-level MR analysis. Ever smoking and previ-
ously smoking increased the risk in line with our observational 
data although current smoking showed no apparent effect on 
risk. Conversely, our individual-level MR provided little evi-
dence for an effect of smoking on Crohn disease or IBD.
Given the discrepancy between our observational anal-
ysis and MR analysis, it may be the case that our MR analysis 
was underpowered to detect an effect. This could be due to (1) 
TABLE 1. The Observed Association of Smoking Behavior and IBD Subtypes Controlling for Age, Sex, and Socio-
Economic Position
Smoking 
Inflammatory Bowel Disease Crohn’s Disease Ulcerative Colitis
P-valueN OR (95% CI) P-value N OR (95% CI) P-value N OR (95% CI)
Ever vs Never 335,467 1.46 (1.37, 1.56) <0.001 335,467 1.50 (1.34, 1.67) <0.001 335,467 1.42 (1.31, 1.54) <0.001
Current vs Former 151,645 0.78 (0.70, 0.88) <0.001 151,645 1.24 (1.05, 1.47) 0.01 151,645 0.57 (0.49, 0.66) <0.001
Cigarettes per day 100,029 1.01 (1.00, 1.01) 0.001 100,029 1.00 (0.99, 1.01) 0.40 100,029 1.01 (1.00, 1.02) 0.001
Lifetime smokinga 335,483 1.22 (1.17, 1.27) <0.001 335,483 1.36 (1.27, 1.45) <0.001 335,483 1.12 (1.06, 1.18) <0.001
aA composite measure of smoking duration, intensity, and cessation. One unit increase in lifetime smoking is equivalent to having smoked 30 cigarettes a day for 17 years and 
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a small causal effect size, (2) weak instrument bias, or (3) our 
sample being too small. It is unlikely that our instrument was 
too weak, given that we have demonstrated the mean F statis-
tics were greater than 10 for both instruments. Furthermore, we 
conducted two-sample summary-level MR with large sample 
sizes (N > 59,000) suggesting a likely explanation for failure 
to clearly demonstrate an effect is in fact any true causal ef-
fect being smaller than that seen in observational data or even 
absent. The observational data may be biased by confounding 
factors or reverse causation, problems that we have overcome 
using an MR design.
In addition, we might not have found evidence for an ef-
fect of smoking because our study focused on risk of  IBD as 
the outcome. Many previous studies have instead found an as-
sociation between progression, symptom severity, or recurrence 
of IBD. For example, in Crohn disease patients, tobacco smoke 
is associated with worse symptoms and a worse clinical course 
of the disease.5 The biological mechanism by which this occurs 
remains unclear due to the chemical complexity of tobacco 
smoke but has been postulated, in both animal and human 
studies, to be due to the effects of nicotine (and perhaps other 
constituents of tobacco) on the immune system and micro-
biota of the gut.32 There is evidence to suggest that this could 
be a causal pathway, given that these effects are associated with 
smoking in a dose-dependent manner33 and that smoking cessa-
tion leads to marked improvement in disease.34
In the case of UC, current smoking has been associ-
ated with improved symptoms and disease course7 compared 
with former smokers. Smoking cessation meanwhile is associ-
ated with a 3-fold increased risk of being diagnosed with UC 
in the 5-year period following cessation.35 A biological mech-
anism has again not been clearly elucidated but there is an 
apparent role for nicotine with several randomized controlled 
trials, demonstrating that nicotine patches help to improve 
symptoms in active UC when compared with placebo patches.36 
Interestingly, nicotine did not have any significant effects over 
placebo in the only randomized controlled trial to investigate 
maintenance of remission in UC,37 which suggests that it does 
not suppress risk of UC. This further supports the notion that 
we might not expect to see effects of cigarette smoking on IBD 
risk and future studies should instead focus on its role in the 
progression and remission of IBD diagnoses. This is currently 
not possible, but methods are currently being developed to ex-
tend MR to be able to do this.38
Strengths and Limitations
The strengths of our study include the use of the MR 
design to reduce bias from reverse causation and residual con-
founding, as well as the many sensitivity analyses conducted to 
strengthen our conclusions. Our genetic instruments for smoking 
were not weak, demonstrated by our tests of instrument strength 
and both of our instruments having been validated previously.14, 
20 We used multiple genetic instruments to capture different 
aspects of smoking behavior, including smoking initiation, life-
time smoking, and smoking heaviness. Our single SNP analysis 
allowed us to focus on a variant with known biological con-
sequence and to include a negative control, both these factors 
reduce the potential for pleiotropy. However, the limitation of 
using a single SNP is reduced statistical power and so this alone 
does not allow us to conclude the absence of an effect. Our single 
SNP instrument also only reflects smoking heaviness and not the 
likelihood of smoking initiation.
As previously discussed, our results suggest that statis-
tical power may have been a limitation of our summary-level 
MR analysis, especially if  the true effect size is small. A strength 
of our study in this regard is good instrument strength and the 
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use of the 2-sample summary-level MR design with both of 
our exposure samples being substantial in size. Therefore, if  the 
study was underpowered, this probably reflects any true causal 
effect being small or absent.
In addition, our observational and individual-level MR sam-
ples had lower prevalence of smoking than the general population 
potentially reducing our power and the generalizability of these 
results. However, we still obtained significant results in our obser-
vational analysis and this issue was not relevant to our summary-
level MR results. Conversely, a strength of our observational and 
individual-level MR analyses was that the prevalence of IBD in the 
samples used were comparable with the general population.
Finally, a limitation of MR studies is possible bias from 
horizontal pleiotropy (where the genetic variants affect the out-
come through pathways other than through the exposure). To 
assess for any pleiotropy, we conducted multiple sensitivity ana-
lyses, for example, the MR Egger intercept. These tests did not 
suggest the presence of bias due to horizontal pleiotropy. Our 
Steiger directionality results also suggest that our results were 
not biased by reverse causation.
CONCLUSIONS
We have not found clear evidence for an effect of smoking 
on the risk of developing IBD using MR analysis. Observational 
associations could be due to residual confounding or reverse 
causation. Future work should aim to explore the effects of 
smoking on IBD maintenance and progression rather than risk 
of onset.
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